Xconomy Awards San Diego CEO Finalists Show How To Build Value
Summary
Another Ionis drug, inotersen (Tegsedi), a treatment for a rare genetic disease called hereditary ATTR amyloidosis, was FDA-approved in October and is now being commercialized by Ionis’s affiliate, Akcea Therapeutics. DeSouza anticipates the PacBio purchase will increase Illumina’s already sizable market and will give researchers and clinicians the tools to gain a more comprehensive picture of the genome—which is becoming more important in this era of precision medicine. Gorman, who was named CEO in 2008, steadied the ship and pushed ahead Neurocrine’s valbenazine (Ingrezza), the first FDA-approved treatment for tardive dyskinesia, a severe side effect of some psychiatric drugs. The company now has 10 drug candidates in its pipeline, including a one-time treatment for the most common vaginal infection in women of reproductive age, which is slated to enter Phase 3 clinical testing this year. Painful finger sticks to measure blood-glucose levels are becoming a thing of the past for people with diabetes, thanks in part to Dexcom (NASDAQ: DXCM ), which makes devices that use disposable sensors inserted under the skin to do continuous glucose monitoring (CGM).
Classifications
AskAI Classifications
LabelsLinked Companies
